InnoCare Pharma Limited (HKG: 9969)

InnoCare Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	6,839	8,287	8,743	5,929	3,970	2,292
Short-Term Investments	-	-	313.29	-	-	-
Trading Asset Securities	244.19	-	-	317.06	-	80.35
Cash & Short-Term Investments	7,083	8,287	9,056	6,246	3,970	2,372
Cash Growth	-14.26%	-8.49%	45.00%	57.34%	67.35%	15.96%
Accounts Receivable	303.97	276.38	127.82	45.27	0.15	0.04
Other Receivables	0.26	31.34	0.99	62.27	78.1	23.39
Receivables	304.24	307.71	128.82	107.55	78.25	23.43
Inventory	93.51	119.09	65.32	9.92	1.88	-
Other Current Assets	387.02	51.38	49.37	53.87	42.46	13.2
Total Current Assets	7,868	8,765	9,300	6,417	4,092	2,409
Property, Plant & Equipment	832.46	798.5	681.5	566.08	403.13	134.79
Long-Term Investments	2.4	5.66	11.71	326.1	1.16	1.16
Goodwill	3.12	3.12	3.12	3.13	3.13	3.13
Other Intangible Assets	259.12	266.03	273.14	34.17	37.02	0.43
Long-Term Deferred Charges	33.03	33.3	39.82	-	-	36.58
Other Long-Term Assets	459.29	48.06	19.77	50.95	1.05	30.86
Total Assets	9,458	9,920	10,329	7,398	4,538	2,616
Accounts Payable	143.07	134.9	118.6	84.6	5.52	8.2
Accrued Expenses	56.69	100.08	119.46	97.5	50.21	10.07
Short-Term Debt	106.05	-	-	-	-	9.1
Current Portion of Long-Term Debt	-	1,251	1,197	-	-	-
Current Portion of Leases	88.87	28.23	20.11	20.34	6.83	6.2
Current Unearned Revenue	0.08	-	4.24	19.48	6.65	0.65
Other Current Liabilities	593.64	567.64	608.09	107.39	35.25	31.46
Total Current Liabilities	1,016	2,082	2,068	329.3	104.45	65.67
Long-Term Debt	1,317	331.88	287.76	1,238	1,150	5,331
Long-Term Leases	35.27	43.65	35.44	47.44	17.17	3.39
Long-Term Unearned Revenue	267.02	281.78	293.58	123.61	100	157.39
Long-Term Deferred Tax Liabilities	-	-	-	-	6.04	6.04
Total Liabilities	2,636	2,739	2,684	1,739	1,377	5,563
Common Stock	0.02	0.02	0.02	0.02	0.02	0
Additional Paid-In Capital	-	12,150	12,082	9,372	6,743	9.34
Retained Earnings	-5,355	-5,080	-4,448	-3,536	-3,544	-3,080
Comprehensive Income & Other	12,154	77.23	-36.31	-230.85	-95.05	66.34
Total Common Equity	6,799	7,148	7,597	5,605	3,104	-3,005
Minority Interest	22.95	32.86	47.23	54.36	56.49	56.96
Shareholders' Equity	6,822	7,181	7,644	5,659	3,161	-2,948
Total Liabilities & Equity	9,458	9,920	10,329	7,398	4,538	2,616
Total Debt	1,547	1,655	1,540	1,306	1,174	5,350
Net Cash (Debt)	5,536	6,632	7,516	4,940	2,796	-2,978
Net Cash Growth	-29.99%	-11.76%	52.15%	76.67%	-	-
Net Cash Per Share	3.23	3.89	5.09	3.62	2.89	-12.96
Filing Date Shares Outstanding	1,891	1,763	1,764	1,500	1,289	300.26
Total Common Shares Outstanding	1,891	1,763	1,764	1,500	1,289	300.26
Working Capital	6,852	6,683	7,232	6,088	3,988	2,343
Book Value Per Share	3.60	4.05	4.31	3.74	2.41	-10.01
Tangible Book Value	6,537	6,879	7,321	5,567	3,064	-3,008
Tangible Book Value Per Share	3.46	3.90	4.15	3.71	2.38	-10.02
Buildings	-	364.63	224.41	81.04	-	-
Machinery	-	302.01	248.14	127.57	13.91	7.51
Construction In Progress	-	166.91	197.65	230.72	296.93	44.36
Leasehold Improvements	-	-	-	6.68	1.08	0.05

Source: S&P Capital IQ. Standard template. Financial Sources.